✦ LIBER ✦

Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro

✍ Scribed by Bendall, L J; Juarez, J; Bradstock, K F; Gottlieb, D J

Book ID: 110055533
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 338 KB
Volume: 17
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2402998

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of the chemokine receptor CXCR7 o

Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo

✍ Meijer, J; Ogink, J; Roos, E 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 57 KB

Effect of the chemokine receptor CXCR7 o

Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo

✍ Meijer, J; Ogink, J; Roos, E 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 368 KB

The role of the CXCR4 cell surface chemo

The role of the CXCR4 cell surface chemokine receptor in glioma biology

✍ Ehtesham, Moneeb; Min, Elliot; Issar, Neil M.; Kasl, Rebecca A.; Khan, Imad S.; 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 725 KB

Histone deacetylase inhibitors synergist

Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells

✍ Eun-Sil Sung; Aeyung Kim; Joon Seong Park; Junho Chung; Myung-Hee Kwon; Yong-Sun 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 764 KB

Effect of a selective Abl tyrosine kinas

Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells

✍ Kawaguchi, Y; Jinnai, I; Nagai, K; Yagasaki, F; Yakata, Y; Matsuo, T; Kuriyama, 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 546 KB

Preclinical testing of the Akt inhibitor

Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia

✍ Camilla Evangelisti; Francesca Ricci; Pierluigi Tazzari; Francesca Chiarini; Mic 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 659 KB

## Abstract Over the past 20 years, survival rates of T‐cell acute lymphoblastic leukemia (T‐ALL) patients have improved, mainly because of advances in polychemotherapy protocols. Despite these improvements, we still need novel and less toxic treatment strategies targeting aberrantly activated sign